Figure 7.
Impact of somatic ERBB family mutations on RFS (left, n = 133) and OS (right, n = 134) after adjuvant trastuzumab-based therapy in our sample set. p-values were calculated using the log rank (Mantel–Cox) test with Graphpad Prism. ERBB family mutations were identified using Agena’s MassARRAY mass spectrometry-based genotyping platform.
OS, overall survival; RFS, relapse-free survival.